Corinne Molyneux

Corinne Molyneux

Auto-generated profile, based on publicly available information

Corinne Molyneux

Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in SLAS Discovery
Verified
Journal Article
Open access
RMRachel Moore
Rachel Moore
CMCorinne Molyneux
Corinne Molyneux
ISIan Sinclair
Ian Sinclair
GHGeoffrey A. Holdgate
Geoffrey A. Holdgate
JWJarrod Walsh
Jarrod Walsh
Rapid triage of compounds acting via undesired mechanisms is a crucial stage in a high-throughput screening (HTS) cascade to ensure time and resource is efficiently assigned to the most propitious hits. Redox cycling compounds (RCCs) produce reactive oxygen species, such as hydrogen peroxide, which can impair protein function and appear as hits against liable targets. Direct measurement of tris(2-carboxyethyl)phosphine (TCEP) oxidation has been demonstrated as a sensitive and accurate measure of redox cycling [1]. However, the current nuclear magnetic resonance (NMR) based detection method is not compatible with the throughput required for triage of a HTS campaign. Here we employ Acoustic Mist Ionisation Mass Spectrometry (AMI-MS) [2] to rapidly measure oxidation of TCEP and accurately identify redox cyclers in a high throughput manner.

18 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCorinne Molyneux
Corinne Molyneux
RORhianna O'SUllivan
Rhianna O'SUllivan
EMEoghan Mulholland
Eoghan Mulholland
JMJoshua William Moore
Joshua William Moore
NLNick Li
Nick Li
CTChristopher J. Tape
Christopher J. Tape
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.